GlassScriptPhysician profile
Ariana Neddermann
NPI 1548049471
$8,498.18
in general payments reported to CMS, 2019-2025
53 companies · $4,068 in 2025
The $4,068 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $454 · 2024: $3,976 · 2025: $4,068.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,475 · Long Term Medical Supply Or Device Loan: $1,280 · Education: $744.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,474.83 |
| Long Term Medical Supply Or Device Loan | $1,279.73 |
| Education | $743.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,863.39 | 2023-2025 | |
| Janssen Biotech, INC. | $526.93 | 2024-2025 | Erleada, Talvey, Tecvayli |
| Merck Sharp & Dohme LLC | $517.91 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Daiichi Sankyo INC. | $450.24 | 2023-2025 | Enhertu, Datroway |
| Takeda Pharmaceuticals U.S.A., INC. | $305.27 | 2023-2025 | Fruzaqla, Ninlaro, Advate |
| Incyte Corporation | $303.22 | 2023-2025 | Monjuvi, Jakafi, Zynyz |
| Pfizer INC. | $274.82 | 2023-2025 | |
| Sobi, INC | $274.40 | 2024-2025 | |
| Eisai INC. | $268.51 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $259.25 | 2023-2025 | |
| Astellas Pharma US INC | $242.92 | 2024-2025 | Xtandi, Xospata, Padcev |
| Abbvie INC. | $214.41 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $193.71 | 2023-2025 | Enhertu, Tagrisso, Lynparza |
| Exelixis INC. | $192.10 | 2023-2025 | Cabometyx |
| E.R. Squibb & Sons, L.L.C. | $179.39 | 2024-2025 | Opdivo, Opdualag |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beone Medicines USA, INC. | $170.89 | 2025 | Brukinsa |
| Genzyme Corporation | $166.51 | 2024-2025 | |
| Adc Therapeutics America, INC. | $127.16 | 2024-2025 | |
| Taiho Oncology, INC. | $115.82 | 2024-2025 | |
| Seagen INC. | $99.99 | 2025 | |
| Genentech USA, INC. | $96.84 | 2023-2025 | Polivy, Tecentriq, Phesgo |
| Ipsen Biopharmaceuticals, INC | $94.88 | 2024-2025 | Onivyde, Somatuline Depot |
| Sun Pharmaceutical Industries INC. | $94.31 | 2024-2025 | |
| Pharmaessentia USA Corporation | $90.26 | 2024-2025 | Besremi |
| Sanofi-Aventis U.S. LLC | $89.99 | 2024 | |
| Cumberland Pharmaceuticals, INC. | $86.09 | 2024-2025 | Sancuso |
| Beigene USA, INC. | $80.45 | 2024 | Brukinsa |
| Rigel Pharmaceuticals, INC. | $73.36 | 2023-2025 | Rezlidhia, Tavalisse, Gavreto |
| Karyopharm Therapeutics INC. | $71.31 | 2023-2025 | Xpovio |
| Blueprint Medicines Corporation | $63.87 | 2024-2025 | Ayvakit |
| Genmab U.S., INC. | $61.56 | 2024-2025 | Epkinly |
| Lilly USA, LLC | $59.51 | 2024-2025 | Jaypirca, Verzenio, Retevmo |
| Aveo Pharmaceuticals, INC. | $57.82 | 2024-2025 | |
| Puma Biotechnology, INC. | $57.58 | 2024-2025 | |
| Dendreon Pharmaceuticals LLC | $56.54 | 2025 | Provenge |
| Boston Scientific Corporation | $54.32 | 2025 | Therasphere Y90 Glass Microspheres 7.0 Gbq (US Commercial) |
| Emd Serono, INC. | $53.61 | 2024 | |
| Jazz Pharmaceuticals INC. | $53.36 | 2024-2025 | |
| Syndax Pharmaceuticals, INC. | $52.62 | 2025 | |
| Stemline Therapeutics INC. | $50.20 | 2024 | Orserdu |
| Coherus Oncology, INC. | $45.36 | 2025 | Loqtorzi |
| Glaxosmithkline, LLC. | $44.57 | 2023-2025 | Ojjaara |
| Deciphera Pharmaceuticals INC. | $41.63 | 2024-2025 | Qinlock, Romvimza |
| Iovance Biotherapeutics, INC. | $34.18 | 2025 | Amtagvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.44 | 2024 | Gilotrif |
| Legend Biotech USA INC. | $27.61 | 2025 | Carvykti |
| Morphosys, US INC. | $23.61 | 2024 | Monjuvi |
| Geron Corporation | $22.15 | 2025 | Rytelo |
| Alexion Pharmaceuticals, INC. | $21.98 | 2024 | Ultomiris |
| Ge Healthcare | $21.33 | 2025 | |
| Agios Pharmaceuticals, INC. | $14.35 | 2025 | Pyrukynd |
| Mirati Therapeutics, INC. | $13.97 | 2024 | Krazati |
| Chiesi USA, INC. | $13.68 | 2024 | Ferriprox |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ariana Neddermann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.